Tango Therapeutics Executive Chair Barbara Weber departs effective August 3, 2026

Tango Therapeutics, Inc.

Dr. Weber's employment ended Aug 3, 2026; she resigned from all officer and board positions.
Resignation not due to any disagreement with the Company's operations, practices or policies.
Severance includes base salary through Dec 31, 2026, COBRA reimbursement, and 12-month vesting acceleration.
Vested stock option exercise period extended to Aug 3, 2027; pro-rata 2026 annual incentive offered.
Benefits contingent on execution of a Separation Agreement; no successor named.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.